Top-line data indicate statistically significant improvement in ACR20 responses over placebo PRINCETON, N.J., May 14 -- Medarex, Inc. (Nasdaq: MEDX) today announced that the MDX-1100 Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results